AR118560A2 - Métodos y composiciones que comprenden polipéptidos recombinantes purificados - Google Patents

Métodos y composiciones que comprenden polipéptidos recombinantes purificados

Info

Publication number
AR118560A2
AR118560A2 ARP200100914A ARP200100914A AR118560A2 AR 118560 A2 AR118560 A2 AR 118560A2 AR P200100914 A ARP200100914 A AR P200100914A AR P200100914 A ARP200100914 A AR P200100914A AR 118560 A2 AR118560 A2 AR 118560A2
Authority
AR
Argentina
Prior art keywords
less
methods
purified recombinant
recombinant polypeptides
compositions including
Prior art date
Application number
ARP200100914A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR118560A2 publication Critical patent/AR118560A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)

Abstract

Se proporcionan polipéptidos recombinantes purificados aislados de células huésped de ovario de hámster chino, incluyendo anticuerpos tales como anticuerpos terapéuticos y métodos de preparación y uso de tales polipéptidos. Reivindicación 1: Una composición que comprende un anticuerpo monoclonal anti-IL13 purificado de células huésped de ovario de hámster chino, en donde la composición comprende el anticuerpo anti-IL13 y una cantidad residual de hámster PLBL2, en donde la cantidad de PLBL2 de hámster es inferior a 20 ng/mg o inferior a 15 ng/mg o inferior a 10 ng/mg o inferior a 8 ng/mg o inferior a 5 ng/mg o inferior a 3 ng/mg o inferior a 2 ng/mg o inferior a 1 ng/mg o inferior a 0,5 ng/mg.
ARP200100914A 2013-09-13 2020-04-01 Métodos y composiciones que comprenden polipéptidos recombinantes purificados AR118560A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361877517P 2013-09-13 2013-09-13

Publications (1)

Publication Number Publication Date
AR118560A2 true AR118560A2 (es) 2021-10-20

Family

ID=52666315

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140103417A AR097651A1 (es) 2013-09-13 2014-09-12 Métodos y composiciones que comprenden polipéptidos recombinantes purificados
ARP200100914A AR118560A2 (es) 2013-09-13 2020-04-01 Métodos y composiciones que comprenden polipéptidos recombinantes purificados

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP140103417A AR097651A1 (es) 2013-09-13 2014-09-12 Métodos y composiciones que comprenden polipéptidos recombinantes purificados

Country Status (18)

Country Link
US (7) US9920120B2 (es)
EP (3) EP4331605A3 (es)
JP (4) JP6751344B2 (es)
KR (2) KR102571391B1 (es)
CN (1) CN105722532A (es)
AR (2) AR097651A1 (es)
AU (2) AU2014318615B2 (es)
BR (1) BR112016004413A2 (es)
CA (2) CA2921999C (es)
HK (1) HK1225988A1 (es)
IL (1) IL244149A0 (es)
MX (3) MX2016003202A (es)
MY (2) MY176026A (es)
NZ (3) NZ756749A (es)
RU (1) RU2671481C2 (es)
SG (2) SG11201601823TA (es)
WO (1) WO2015038888A1 (es)
ZA (4) ZA201601965B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3936515A1 (en) 2013-03-15 2022-01-12 Biogen MA Inc. Hydrophobic interaction protein chromatography under no-salt conditions
SG11201601823TA (en) * 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
TW201702380A (zh) 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
CA2995385A1 (en) * 2015-08-20 2017-02-23 Genentech, Inc. Purification of fkpa and uses thereof for producing recombinant polypeptides
IL257146B1 (en) * 2015-08-21 2024-09-01 Hoffmann La Roche A method for reducing host cell proteins in affinity chromatography
ES2897965T3 (es) * 2015-08-21 2022-03-03 Hoffmann La Roche Procedimiento para la reducción de proteínas de célula huésped en cromatografía de afinidad
EP3443348A1 (en) * 2016-04-14 2019-02-20 Lonza Ltd Compositions and methods for the detection of host cell proteins
CA3031028C (en) * 2016-07-25 2024-02-13 Lu Wang Affinity chromatography wash buffer
KR102369014B1 (ko) 2016-08-16 2022-03-02 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
SG11201901059QA (en) 2016-09-07 2019-03-28 Glaxosmithkline Ip Dev Ltd Methods for purifying antibodies
CN109790216A (zh) * 2016-10-06 2019-05-21 葛兰素史克知识产权开发有限公司 与工艺杂质的结合降低的抗体
WO2018081203A1 (en) 2016-10-25 2018-05-03 Regeneron Pharmaceuticals, Inc. Methods and systems for chromatography data analysis
AU2017380842A1 (en) 2016-12-23 2019-07-11 Serum Institute Of India Private Limited Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
TW202003555A (zh) * 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
AU2019299321A1 (en) 2018-07-02 2021-01-07 Regeneron Pharmaceuticals, Inc. Use of multiple hydrophobic interaction chromatography for preparing a polypeptide from a mixture
EP3826743A4 (en) * 2018-07-25 2022-09-14 Merck Sharp & Dohme Corp. METHODS FOR SEPARATION OF HOST CELL LIPASES FROM A PRODUCTION PROTEIN IN CHROMATOGRAPHIC METHODS
AU2020213017A1 (en) 2019-01-23 2021-07-22 Daiichi Sankyo Company, Limited Methods for purifying antibodies comprising of a process by using activated carbon materials
WO2020157749A1 (en) * 2019-01-29 2020-08-06 Bnai Zion Medical Center Anti il-17 antibody for use in treating chronic spontaneous urticaria
US20220314142A1 (en) * 2019-07-01 2022-10-06 Pfizer Inc. Improvements to wash solutions for protein a chromatography in an antibody purification process
KR20220075380A (ko) * 2019-10-04 2022-06-08 메르크 파텐트 게엠베하 단백질 정제 및 바이러스 불활성화
CA3165528A1 (en) * 2020-01-29 2021-08-05 Colette M. Cutler Methods of separating host cell lipases from an anti-lag3 antibody production
EP4334333A1 (en) * 2021-05-03 2024-03-13 Agilent Technologies, Inc. Chimeric immunogens and methods for making polyclonal antibodies against specific epitopes
TW202409060A (zh) * 2022-05-02 2024-03-01 美商再生元醫藥公司 用於降低脂酶活性之方法
WO2024137702A1 (en) * 2022-12-19 2024-06-27 Eli Lilly And Company Methods of reducing contaminants in protein purification
CN117169518B (zh) * 2023-11-03 2024-01-19 赛德特(北京)生物工程有限公司 T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2031216A1 (de) 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Tag und Datum Stellvorrichtung fur Uhren mit Kalender
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3422247A1 (de) 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Gluco-oligosaccharid-gemisch und verfahren zu seiner herstellung
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US4847745A (en) 1988-11-16 1989-07-11 Sundstrand Corp. Three phase inverter power supply with balancing transformer
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5011778A (en) 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2085983T3 (es) 1989-12-20 1996-06-16 Schering Corp Antagonistas de anticuerpos de la interleuquina-4 humana.
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE130869T1 (de) 1991-03-29 1995-12-15 Sanofi Sa Protein mit der aktivität vom typ von cytokin, dafür kodierende rekombinante dns, transformierte zellen und mikroorganismen.
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5994514A (en) 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US5965709A (en) 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
WO1993015766A1 (en) 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens
CA2128862C (en) 1992-02-11 2008-05-20 Jonathan G. Seidman Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
AU680816B2 (en) 1992-05-15 1997-08-14 Quest International B.V. Cloning and expression of DNA encoding a ripening form of a polypeptide having phamnogalacturonase activity
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5596072A (en) 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
JPH07508179A (ja) 1992-08-21 1995-09-14 シェリング・コーポレーション ヒトインターロイキン−１３
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
ES2128562T3 (es) 1993-05-17 1999-05-16 Genentech Inc Celulas deficientes en sialidasa.
ATE188487T1 (de) 1993-09-02 2000-01-15 Dartmouth College Anti-gp39 antikoerper und deren verwendungen
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6518061B1 (en) 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ES2334408T3 (es) 1995-10-23 2010-03-09 Zenyth Operations Pty Ltd Receptor de hematopoyetina y secuencias geneticas que lo codifican.
US6911530B1 (en) 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
HU230515B1 (hu) 1996-02-09 2016-10-28 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazásai
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US7078494B1 (en) 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
AU6450196A (en) 1996-06-12 1998-01-07 Human Genome Sciences, Inc. Hr-1 receptor
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
DK1897890T3 (da) 1996-11-27 2010-04-06 Genentech Inc Affinitetsoprensning af polypeptid på en protein A matrix
US6743604B1 (en) 1996-12-13 2004-06-01 Smithkline Beecham Corporation Substances and their uses
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
KR20000070034A (ko) 1997-01-10 2000-11-25 아스트루 마이클 제이 항 ｃｄ40ｌ 화합물로 신염성 루푸스를 치료하는 방법
NZ336720A (en) 1997-01-22 2001-06-29 Univ Texas A coagulation-deficient tissue factor (TF) compound [e.g. IgG-H6-N'-cys-tTF219] that is at least 100 times less active than the native form and its use against vascular tumour
US6576232B1 (en) 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
US6482403B1 (en) 1998-05-29 2002-11-19 Heska Corporation Caniney IL-13 immunoregulatory proteins and uses thereof
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
GB9820014D0 (en) 1998-09-14 1998-11-04 Cancer Res Campaign Tech Receptor antagonists and uses thereof
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
DE19848026A1 (de) 1998-10-17 2000-04-20 Bayer Ag Verfahren zur Herstellung von Bis(4-hydroxyaryl)alkanen
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US7507706B1 (en) 1998-12-14 2009-03-24 Genetics Institute, Llc Cytokine receptor chain
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US6468528B1 (en) 1999-02-01 2002-10-22 Amgen Canada Inc. Materials and methods to inhibit Hodgkin and Reed Sternberg cell growth
AU1599301A (en) 1999-11-11 2001-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Modulating IL-13 activity using mutated IL-13 molecules that are antagonists or agonists of IL-13
US20100041039A1 (en) 2000-01-15 2010-02-18 Synageva Biopharma Corp. Analysis of nucleic acid obtained from nucleated red blood cells
PL218883B1 (pl) 2000-02-24 2015-02-27 Lilly Co Eli Kompozycja farmaceutyczna zawierająca przeciwciało do zastosowania w leczeniu klinicznej lub przedklinicznej choroby Alzheimera
ES2309050T3 (es) 2000-03-03 2008-12-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo anti-ccr4 y su fragmento.
CN1323812A (zh) 2000-05-16 2001-11-28 上海博德基因开发有限公司 一种新的多肽——人白细胞介素－13(il－13)受体11和编码这种多肽的多核苷酸
ES2311558T3 (es) 2000-10-20 2009-02-16 Genetics Institute, Inc. Uso de inhibidores de la il-13 para el tratamiento de tumores.
AU1091802A (en) 2000-10-20 2002-04-29 Chugai Pharmaceutical Co Ltd Degraded agonist antibody
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
ATE519783T1 (de) 2000-12-22 2011-08-15 Grad Carole Legal Representative Of Kaplan Howard ßPHAGE DISPLAYß BIBLIOTHEKE VON MENSCHLICHEN VH FRAGMENTEN
EP1411983A4 (en) 2001-06-26 2006-06-21 Imclone Systems Inc BISPECIFIC ANTIBODIES BINDING TO VEGF RECEPTORS
US20030023555A1 (en) 2001-07-26 2003-01-30 Cashworks, Inc. Method and system for providing financial services
BRPI0212266B8 (pt) 2001-08-31 2021-05-25 Kyowa Hakko Kirin Co Ltd anticorpos humanizados anti-ccr4, método de produção dos mesmos, medicamento, e agentes terapêuticos e de diagnóstico
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20040023337A1 (en) 2001-10-26 2004-02-05 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
ES2320638T3 (es) 2001-11-07 2009-05-27 Cytos Biotechnology Ag Disposicion ordenada de antigenos il-5, il-13 o eotasina, para el tratamiento de enfermedades alergicas con un componente eosinofilico.
ATE417858T1 (de) 2002-02-05 2009-01-15 Genentech Inc Proteinaufreinigung
WO2003086451A1 (en) 2002-04-05 2003-10-23 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
US20040060102A1 (en) 2002-04-10 2004-04-01 Interspiro, Inc. Garments for biological, chemical and fire protection
HUE025101T2 (en) 2002-04-26 2016-02-29 Genentech Inc Purification of proteins other than affinity purification
WO2004001655A1 (en) 2002-06-14 2003-12-31 The Govermment Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Office Of Technology Transfer Methods of treating and preventing colitis involving il-13 and nk-t cells
JP2006501249A (ja) 2002-08-30 2006-01-12 グラクソ　グループ　リミテッド ワクチン
TW200407162A (en) 2002-08-30 2004-05-16 Glaxo Group Ltd Vaccine
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
EP1596809B1 (en) 2003-02-10 2010-05-26 Applied Molecular Evolution, Inc. Abeta binding molecules
US7157276B2 (en) 2003-06-20 2007-01-02 Biogen Idec Inc. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
EP1639011B1 (en) 2003-06-30 2008-11-12 Domantis Limited Pegylated single domain antibodies (dAb)
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
SG10201900535UA (en) 2003-12-23 2019-02-27 Genentech Inc Novel anti-il 13 antibodies and uses thereof
US20090324604A1 (en) 2004-01-07 2009-12-31 Chiron Corporation M-csf specific monoclonal antibody and uses thereof
WO2005071410A1 (en) 2004-01-13 2005-08-04 Tanox, Inc. Detecting and quantifying host cell proteins in recombinant protein products
JP2008507253A (ja) 2004-02-06 2008-03-13 ナイモックス コーポレーション ヒト化抗体
PL1720909T3 (pl) 2004-02-23 2012-04-30 Lilly Co Eli Przeciwciało anty-abeta
US20070037966A1 (en) * 2004-05-04 2007-02-15 Novo Nordisk A/S Hydrophobic interaction chromatography purification of factor VII polypeptides
ES2339953T5 (es) 2004-05-04 2020-05-06 Novo Nordisk Healthcare Ag Glicoformas de factor VII ligadas a O y método de fabricación
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
AU2005299716B2 (en) 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
WO2006066308A1 (en) 2004-12-24 2006-06-29 Commonwealth Scientific And Industrial Research Organisation Pesticide compositions and methods
WO2006099308A2 (en) 2005-03-11 2006-09-21 Wyeth A method of weak partitioning chromatography
WO2006110277A1 (en) 2005-04-11 2006-10-19 Medarex, Inc. Protein purification using hcic amd ion exchange chromatography
KR101247836B1 (ko) 2005-06-17 2013-03-28 와이어쓰 엘엘씨 항 ａ 베타 항체의 정제 방법
JP3982545B2 (ja) 2005-09-22 2007-09-26 ダイキン工業株式会社 空気調和装置
KR101363777B1 (ko) 2005-09-30 2014-02-14 메디뮨 리미티드 인터루킨―１３ 항체 조성물
PT2532679T (pt) 2005-10-21 2017-07-18 Novartis Ag Anticorpos humanos contra il13 e utilizações terapêuticas
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
US7667557B2 (en) 2005-12-06 2010-02-23 Tdk Corporation Thin-film bandpass filter using inductor-capacitor resonators
KR101505201B1 (ko) 2005-12-12 2015-03-24 에이씨 이뮨 에스.에이. 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
UY30003A1 (es) 2005-12-12 2007-08-31 Hoffmann La Roche Anticuerpos glicosilados en la region variable
ES2382164T3 (es) 2005-12-30 2012-06-05 Merck Patent Gmbh Anticuerpos anti-IL-6 que impiden la unión de la IL-6 en complejo con el IL-6R( ) a la GP130
US7563875B2 (en) 2006-03-20 2009-07-21 The United States of America as represented by the Sercretary of the Army Recombinant chimeric human anti-botulinum antibodies
NZ611859A (en) * 2006-04-05 2014-12-24 Abbvie Biotechnology Ltd Antibody purification
JP2009534035A (ja) 2006-04-21 2009-09-24 ワイス 細胞系のハイスループットスクリーニング方法
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US8637290B2 (en) 2006-09-21 2014-01-28 Dsm Ip Assets B.V. Phospholipases, nucleic acids encoding them and methods for making and using them
CN101611054B (zh) 2006-10-02 2013-12-25 Ac免疫有限公司 针对淀粉状蛋白β的人源化抗体
RS53387B (en) 2006-10-04 2014-10-31 Genentech, Inc. ELISA FOR VEGF
US8383350B1 (en) 2006-12-20 2013-02-26 Merck Sharp & Dohme Corp. Assay for detection of IL-10 antibodies
CA2674608A1 (en) 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
WO2008140455A1 (en) 2007-05-15 2008-11-20 Tanox, Inc. Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies
NZ581834A (en) 2007-06-12 2012-06-29 Ac Immune Sa Humanized antibodies to amyloid beta
MX2009013503A (es) 2007-06-12 2010-01-27 Genentech Inc Anticuerpo monoclonal anti-amiloide-beta.
US9433922B2 (en) 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
UA101167C2 (ru) 2007-10-05 2013-03-11 Дженентек, Инк. Фармацевтическая композиция, предназначенная для лечения глазной болезни
US20100297012A1 (en) 2007-10-05 2010-11-25 Andrea Pfeifer Humanized antibody
BRPI0818643A2 (pt) 2007-10-05 2017-05-23 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga de placa na camada celular de gânglio retinal de um paciente, para reduzir a quantidade de placas na camada celular de gânglio retinal de um paciente, para diminuir a quantidade total de amilóide-beta solúvel na camada celular de gânglio retinal de um paciente, para evitar, tratar ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para diagnosticar uma predisposição a uma doença ocular associada com anormalidades patológicas/mudanças nos tecidos dos sistema visual, para monitorar doenças ocular mínima residual associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer a responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um paciente
WO2009058769A1 (en) * 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
KR102070761B1 (ko) 2008-03-31 2020-01-29 제넨테크, 인크. 천식을 치료 및 진단하기 위한 조성물 및 방법
WO2009131643A1 (en) 2008-04-21 2009-10-29 Monabio, Inc. Immunoassay for specific determination of s-adenosymethionine and analogs thereof in biological samples
NZ600584A (en) 2008-05-05 2014-05-30 Novimmune Sa Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
ES2502940T3 (es) 2008-08-05 2014-10-06 Toray Industries, Inc. Composición farmacéutica para el tratamiento y la prevención del cáncer
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
GB0818674D0 (en) 2008-10-10 2008-11-19 Univ Bath Materials and methods for resolving polyhydric species by electrophoresis
BRPI0919545A2 (pt) 2008-10-20 2015-12-08 Abbott Lab anticorpos que se ligam a il-18 e métodos de purificar os mesmos
BRPI0920027A2 (pt) 2008-10-20 2015-10-06 Abbott Lab isolamento e purificação de anticorpos usando cromatografia de afinidade a proteína a
BRPI0919547A2 (pt) 2008-10-20 2015-12-08 Abbott Lab anticorpos que se ligam a il-12 e métodos de purificação do mesmo
JP5856845B2 (ja) 2008-10-20 2016-02-10 アッヴィ・インコーポレイテッド 抗体精製中におけるウイルスの不活性化
CN101979404B (zh) 2008-12-09 2015-01-14 厦门大学 H5亚型禽流感病毒保守中和表位模拟肽及其用途
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
WO2011010940A1 (en) 2009-07-19 2011-01-27 Serguei Zavtrak Solar electric power generator
NZ597809A (en) 2009-08-06 2014-05-30 Genentech Inc Method to improve virus removal in protein purification
CN102574924A (zh) 2009-09-03 2012-07-11 先灵公司 抗-gitr抗体
UA109884C2 (uk) 2009-10-16 2015-10-26 Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
DK3037104T3 (da) 2009-10-20 2020-07-20 Abbvie Inc Isolering og renselse af anti-il-13 antistoffer ved brug af protein a beslægtet kromatografi
HRP20211444T1 (hr) 2010-01-29 2021-12-24 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antitijelo
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
EA030226B1 (ru) 2010-03-04 2018-07-31 Макродженикс, Инк. Антитела, реактивные к b7-h3, их иммунологически активные фрагменты и их применения
EP3181149A1 (en) 2010-05-14 2017-06-21 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
JP5859434B2 (ja) 2010-05-17 2016-02-10 株式会社カイオム・バイオサイエンス ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＴＲＯＰ−２抗体
AU2011258254B2 (en) 2010-05-25 2016-01-07 Genentech, Inc. Methods of purifying polypeptides
JP2013533746A (ja) 2010-07-06 2013-08-29 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｒｏｎ抗体
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
PE20140195A1 (es) 2010-09-29 2014-02-24 Genentech Inc Composiciones de anticuerpo y metodos de uso
TWI689314B (zh) * 2010-11-30 2020-04-01 建南德克公司 低親和力血腦障壁受體抗體及其用途
KR101615420B1 (ko) 2010-12-16 2016-04-26 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
EP2773439A4 (en) * 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR DECOMPOSING HETEROGENEOUS ANTIBODY AGGREGATES
CA3078979C (en) * 2011-10-31 2022-10-11 Genentech, Inc. Formulation comprising an anti-il13 antibody having extended stability
JP2014533700A (ja) * 2011-11-21 2014-12-15 ジェネンテック， インコーポレイテッド 抗ｃ−ＭＥＴ抗体の精製
EP2791176B1 (en) 2011-12-15 2018-07-11 Prestige Biopharma Pte. Ltd. A method of antibody purification
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
AU2013203619B2 (en) 2012-02-29 2015-02-26 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
CA2920686C (en) * 2013-09-13 2022-12-06 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
SG11201601823TA (en) * 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides

Also Published As

Publication number Publication date
JP6982027B2 (ja) 2021-12-17
JP2024059617A (ja) 2024-05-01
JP2022036971A (ja) 2022-03-08
AU2020200502B9 (en) 2022-03-24
IL244149A0 (en) 2016-04-21
MY176026A (en) 2020-07-22
ZA201601965B (en) 2018-11-28
MX2021005358A (es) 2021-06-30
JP2019178139A (ja) 2019-10-17
HK1225988A1 (zh) 2017-09-22
US10494429B2 (en) 2019-12-03
US20230250165A1 (en) 2023-08-10
JP2016539176A (ja) 2016-12-15
EP3043820A4 (en) 2017-07-12
ZA202101142B (en) 2022-09-28
US10597446B2 (en) 2020-03-24
RU2016108828A (ru) 2017-10-18
SG10201802525QA (en) 2018-04-27
US9920120B2 (en) 2018-03-20
AU2014318615B2 (en) 2020-03-12
CA2921999A1 (en) 2015-03-19
NZ756749A (en) 2022-05-27
CA3184564A1 (en) 2015-03-19
AU2020200502B2 (en) 2022-03-10
US20210115126A1 (en) 2021-04-22
EP3043820A1 (en) 2016-07-20
US11667706B2 (en) 2023-06-06
JP7489953B2 (ja) 2024-05-24
EP3683232A1 (en) 2020-07-22
US20180291095A1 (en) 2018-10-11
ZA201801849B (en) 2021-07-28
EP4331605A3 (en) 2024-05-22
SG11201601823TA (en) 2016-04-28
US20160319012A1 (en) 2016-11-03
KR102571391B1 (ko) 2023-08-29
WO2015038888A9 (en) 2016-03-17
AU2014318615A1 (en) 2016-04-21
US10597447B2 (en) 2020-03-24
MX2021005364A (es) 2021-06-30
KR20160052724A (ko) 2016-05-12
WO2015038888A1 (en) 2015-03-19
CN105722532A (zh) 2016-06-29
ZA202201361B (en) 2023-11-29
NZ718144A (en) 2022-05-27
US10822404B2 (en) 2020-11-03
EP4331605A2 (en) 2024-03-06
RU2671481C2 (ru) 2018-10-31
RU2016108828A3 (es) 2018-05-29
NZ756750A (en) 2022-05-27
BR112016004413A2 (pt) 2017-10-17
AU2020200502A1 (en) 2020-02-13
AU2014318615A9 (en) 2016-06-16
KR102373930B1 (ko) 2022-03-11
JP6751344B2 (ja) 2020-09-02
KR20220034930A (ko) 2022-03-18
CA2921999C (en) 2023-03-21
MX2016003202A (es) 2016-06-07
AR097651A1 (es) 2016-04-06
US20180291094A1 (en) 2018-10-11
MY193481A (en) 2022-10-17
US20180273615A1 (en) 2018-09-27
US20180312585A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
AR118560A2 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
ECSP18066138A (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
BR112018007017A2 (pt) polipeptídeos
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
MX2016007063A (es) Peptidos terapeuticos.
GT201400111A (es) Triazolopiridinas sustituidas
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
EA201391136A1 (ru) Лиофилизированные составы
CL2016002245A1 (es) Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
BR112019008351A2 (pt) imunoglobulinas e usos das mesmas
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
MX2017003211A (es) Anticuerpos anti-met y composiciones.
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
PE20170088A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
MX2015012812A (es) Medicamentos novedosos que comprenden una composicion de anticuerpo enriquecida con isoforma de carga mayor.